This project was supported by federal Harold Rogers Grant No. 2016-PM-BX-0003 awarded by the Bureau of Justice Assistance. The Bureau of Justice Assistance is a component of the Department of Justice’s Office of Justice Programs, which also includes the Bureau of Justice Statistics, the National Institute of Justice, the Office of Juvenile Justice and Delinquency Prevention, the Office for Victims of Crime, and the SMART Office. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the U.S. Department of Justice.
Table of Contents

1 INTRODUCTION .................................................................................................................. 3
  1.1 BACKGROUND ............................................................................................................... 3
  1.2 PRESCRIBER REPORT CARD OVERVIEW ................................................................. 3

2 KENTUCKY LICENSURE BOARD ANNUAL REPORT CARD CERTIFICATION REQUIREMENTS .................................................... 3

3 ACCESSING THE PRESCRIBER REPORT CARD ................................................................ 4
  3.1 MASTER ACCOUNT HOLDER ACCESS ........................................................................... 4
  3.1.1 Master Account Holder – Account Details Page ....................................................... 4
  3.2 AUTHORIZED DELEGATE ACCOUNT HOLDER ACCESS ............................................. 5
  3.2.1 Delegate Account – Landing Page .............................................................................. 6
  3.2.2 Prescriber Report Card, Delegate View .................................................................... 6

4 PRESCRIBER REPORT CARD SPECIFICATIONS ................................................................ 8
  4.1 HOW THE PRESCRIBER REPORT CARD IS GENERATED ........................................... 8
  4.2 PRESCRIBER DEA NUMBER(s) ..................................................................................... 8
  4.3 SPECIALTY AREAS ....................................................................................................... 9
  4.4 OPIOID/BUPRENORPHINE CONSIDERATIONS .......................................................... 10
  4.5 MORPHINE MILLIGRAM EQUIVALENT DOSE INFORMATION ..................................... 10
  4.6 PRESCRIBER REPORT CARD CALCULATIONS ............................................................ 10
    4.6.1 Patients receiving three or more days of overlapping opioid prescriptions from all prescribers .................................................. 10
    4.6.2 Patients receiving overlapping opioid and benzodiazepine/sedative prescriptions from all prescribers ........................................... 11
    4.6.3 Patients for whom you prescribed benzodiazepines or sedatives ................................................................. 11
    4.6.4 Patients for whom you prescribed stimulants .......................................................... 11
    4.6.5 Patients for whom you prescribed opioids excluding buprenorphine products .......................................................... 12
    4.6.6 Average daily morphine milligram dosage for your patients receiving opioids excluding buprenorphine products .................. 12
    4.6.7 Patients for whom you prescribed buprenorphine medication assisted treatment products .................................................... 12
    4.6.8 Average daily milligram dosage for your patients receiving buprenorphine medication assisted treatment products .................. 12
    4.6.9 Patients receiving controlled substance prescriptions from five or more different prescribers .................................................. 12
    4.6.10 Prescribing comparison for opioids excluding buprenorphine products .................. 13
    4.6.11 Prescribing comparison for benzodiazepines ......................................................... 13
    4.6.12 Prescribing comparison for sedatives ................................................................. 14
    4.6.13 Prescribing comparison for stimulants ................................................................. 14
    4.6.14 Average daily morphine milligram equivalent for patients receiving opioids excluding buprenorphine .................................. 14
  4.7 MEDICATION ASSISTED TREATMENT METRICS ....................................................... 15

5 PRESCRIBER REPORT CARD EXAMPLE ......................................................................... 16
1 Introduction

1.1 Background

One of the recent enhancements to several state Prescription Drug Monitoring Programs (PDMPs) is a prescriber dashboard or prescriber report card. In order to conform with this PDMP “best practice” the Cabinet for Health and Family Services (CHFS) has developed a Prescriber Report Card function within the Enhanced Kentucky All Schedule Prescription Electronic Reporting (eKASPER) system. This report card reflects a consolidated dashboard view of prescribing patterns and trends for a given prescriber along with his/her standings compared to state and specialty averages. The eKASPER Prescriber Report Card replaces the Prescriber Peer Review Report, but contains the data that was included in the peer review report along with additional information to assist Kentucky prescribers to assess their controlled substance prescribing patterns.

1.2 Prescriber Report Card Overview

The eKASPER Prescriber Report Card was designed in collaboration with Kentucky prescriber licensure boards and other stakeholders. eKASPER prescriber master account holders can access quarterly and annual (calendar year) prescriber report cards. Prescriber master account holders may also authorize one or more of their delegates to access a prescriber report card on the master account holder’s behalf. The system also provides the capability for prescribers to certify that they reviewed their annual prescriber report card if required by a Kentucky prescriber licensure board. Please refer to Section 2 Kentucky Licensure Board Annual Report Card Certification Requirements for the status of licensure board prescriber annual report card certification requirements. Prescriber report cards are prepared on a quarterly and calendar year basis using KASPER controlled substance prescription data for those periods. The quarterly and annual prescriber report cards present the data in the same format. Prescriber master account holders and their authorized delegates can view online or download PDF versions of the two most recent annual report cards and the four most recent quarterly report cards.

For questions or suggestions regarding the eKASPER Prescriber Report Card, please send an email to eKASPER.Admin@ky.gov.

2 Kentucky Licensure Board Annual Report Card Certification Requirements

Kentucky licensure board annual report card review certification requirements as of January 11, 2018.

<table>
<thead>
<tr>
<th>Kentucky Licensure Board</th>
<th>Certification Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kentucky Board of Dentistry</td>
<td>Not Required</td>
</tr>
<tr>
<td>Kentucky Board of Medical Licensure</td>
<td>Not Required</td>
</tr>
<tr>
<td>Kentucky Board of Nursing</td>
<td>Not Required</td>
</tr>
<tr>
<td>Kentucky Board of Optometric Examiners</td>
<td>Not Required</td>
</tr>
<tr>
<td>Kentucky Board of Podiatry</td>
<td>Not Required</td>
</tr>
</tbody>
</table>
3 Accessing the Prescriber Report Card

This section provides instructions on how master account holders can access their prescriber report cards; how master account holders can authorize one or more of their delegates to access the prescriber report cards on their behalf; and how authorized delegates can access the prescriber report card for the master account holder.

3.1 Master Account Holder Access

Master account holders can request their quarterly and annual prescriber report cards and manage their delegate authorizations to access the prescriber report cards on their behalf. Master account holders can also certify they have reviewed their annual report card if required by their licensure board.

3.1.1 Master Account Holder – Account Details Page

The first step is for master account holders to log into their eKASPER account and select Administration from the left navigation menu of the Request Report web page. This will display the following Account Maintenance web page.

3.1.1.1 Annual Report Card Review and [Certification]

In the Prescriber Report Card section on this web page, the Annual Report Cards section has a drop down menu that allows selection of one of the two most recent annual prescriber report cards.
Please note: the first annual prescriber report card will be prepared for calendar year 2017. Annual prescriber report cards will not be available for prior years and new Kentucky prescribers may not initially have a prior year annual report card.

After selecting the desired annual report card, Clicking View Report Card displays the selected annual report card in PDF format for viewing, printing or downloading.

Annual Report Card Certification
Prescribers will be notified if their licensure board requires them to certify they have reviewed their annual prescriber report card. Please refer to Section 2 Kentucky Licensure Board Annual Report Card Certification Requirements for the status of licensure board review and certification requirements. If the most recent annual report card has not been certified as reviewed, the Certify Annual Report button will be visible. Clicking on the Certify Annual Report button will display the “Last Verified On” message along with the current date, and log the certification date for compliance reporting to the licensure boards. The Certify Annual Report button is enabled and visible only if the most recent annual report card has not been certified.

3.1.1.2 Quarterly Prescriber Report Card Review

In the Prescriber Report Card section on this web page, the Quarterly Report Cards section has a dropdown menu that shows the four most recent quarterly report cards for the master account holder, and allows selection of any one of those quarterly report cards. After selecting the desired quarterly report card, Clicking View Report Card displays the selected quarterly report card in PDF format for viewing, printing or downloading.

Please note: the first quarterly prescriber report card will be prepared for 4Q of calendar year 2017. Quarterly prescriber report cards will not be available for prior quarters and new Kentucky prescribers may not initially have prior quarterly report cards.

3.1.1.3 Prescriber Report Card Delegate Authorization Management

The table of delegates in the Delegate Account Information section on this web page includes a column with the header “Report Card Authorization”. The table lists each of the delegates under the master account holder along with a status of “Authorized” or “Not Authorized”. Master account holders have the option to authorize one or more delegates to access the quarterly and annual prescriber report cards on their behalf by clicking on the Authorize action button for an individual delegate. When a delegate is authorized, the master account holder may remove that authorization at any time by clicking on the Deauthorize action button. Authorized delegates can view and download prescriber report cards only. Delegates do not have the ability to certify that an annual report card has been reviewed.

3.2 Authorized Delegate Account Holder Access

Delegates can access the quarterly and annual prescriber report cards for all master account holders who have authorized the delegate to access the prescriber report cards on their behalf.
3.2.1 Delegate Account – Landing Page

When a delegate account holder logs into eKASPER they will see the following Request Report web page.

Clicking Master Reports in the left navigation menu will take the delegate account holder to the following Prescriber Report Card, Delegate View page.

3.2.2 Prescriber Report Card, Delegate View
3.2.2.1 Master Account Selection

The Master Account Selection section on this web page provides a dropdown menu populated with a list of all Master Account Holders who have authorized the delegate to access the master account holder's prescriber report cards. If no master account holders have authorized the delegate to access their prescriber report cards, the dropdown is disabled and the following message is displayed: “No master accounts have authorized you to view prescriber report cards on their behalf.”

If the delegate is authorized under one or more master account holders, the delegate can select the master account holder for whom they are requesting a prescriber report card. Controls in the Quarterly Report Cards and Annual Report Cards sections are initially disabled. Selecting a master account will enable the controls in those sections.

3.2.2.2 Annual Report Card (Delegate)

In the Prescriber Report Card section on this web page, the Annual Report Cards section has a drop down menu that allows selection of one of the two most recent annual prescriber report cards for the selected master account holder. After selecting the desired annual report card, clicking View Report Card displays the selected annual report card in PDF format for viewing, printing or downloading.

3.2.2.3 Quarterly Report Card (Delegate)

In the Prescriber Report Card section on this web page, the Quarterly Report Cards section has a dropdown menu that shows the four most recent quarterly reports for the selected master account holder, and allows selection of any one of those quarterly report cards. After selecting the desired quarterly report card, clicking View Report Card displays the selected quarterly report card in PDF format for viewing, printing or downloading.
4 Prescriber Report Card Specifications

4.1 How the Prescriber Report Card is Generated

The eKASPER Prescriber Report Card information and metrics are based on the prescriber DEA number(s) and area of work (specialty) in the prescriber master account holder’s eKASPER personal account information. Following are parameters used for compiling the prescriber report cards.

1. The quarterly and calendar year annual prescriber report cards are presented in the same format. The Prescriber Report Card Header identifies the specific report card period.
2. The calculations and data are based on controlled substance prescriptions reported to KASPER under the prescriber’s DEA number(s). Only those DEA numbers associated with the prescriber’s eKASPER account are used to select the prescriber specific prescription data used for report card calculations.
3. Compounded controlled substance medications are excluded from the prescriber report cards.
4. Percentage calculations are based on the total number of the prescriber’s patients who received one or more Schedule II through V controlled substances during the prescriber report card time period.
5. Calculations are based on the prescription date written except for: overlapping opioid prescriptions, overlapping opioid and benzodiazepine prescriptions, and patients receiving controlled substance prescriptions from five or more different prescribers. Those three metrics use the prescription date filled for the calculation.
6. Dispensers sometimes report erroneous numbers of doses (reported to KASPER as metric quantity) or the number of days supply for a prescription. The following edits are used for KASPER data collection, so prescription records that do not meet these edit criteria will not be considered in the prescriber report card calculations.
   a. Records are rejected if the dose unit of measure is “each” and the number of doses is greater than 3,000.
   b. Records are rejected if the dose unit of measure is “milliliters” and the number of doses is greater than 10,000.
   c. Records are rejected if the dose unit of measure is “grams” and the number of doses is greater than 3,000.
   d. Records are rejected if the number of days supply is not between 1 and 365.

Following is additional information on prescriber report card data selection and metric calculations.

4.2 Prescriber DEA number(s)

The Prescriber Report Card header lists the prescriber’s DEA number(s) that were used to select the prescription records factored into the report card calculations. The DEA number(s) are those specified in the prescriber’s eKASPER personal account information. All Kentucky prescribers with an eKASPER account have a primary DEA number that was verified when they registered with eKASPER. Prescribers with additional DEA numbers can contact eKASPER administration (eKASPER.Admin@ky.gov) to have the additional DEA numbers added to their eKASPER account information to allow more accurate and complete report card data.
4.3 Specialty Areas

The prescriber specialty is determined based on the current “area of work” in the master account holder’s eKASPER personal account information. Prescriber master account holders may modify their primary area of work by selecting Administration, then Account Maintenance on the Request Report web page. The specialty averages contained in the prescriber report card are based on a grouping of account level areas of work as shown in the following table.

<table>
<thead>
<tr>
<th>Grouped Area of Work</th>
<th>Account Area of Work</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain Management</td>
<td>Pain Management</td>
</tr>
<tr>
<td>Dental/Oral Surgery</td>
<td>Dental/Oral Surgery</td>
</tr>
<tr>
<td>Anesthesiology</td>
<td>Anesthesiology</td>
</tr>
<tr>
<td>Cardiology</td>
<td>Cardiology</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Dermatology</td>
</tr>
<tr>
<td>Emergency Medicine</td>
<td>Emergency Medicine</td>
</tr>
<tr>
<td>Primary Care</td>
<td>Family Practice</td>
</tr>
<tr>
<td></td>
<td>Hospitalist(Internal Medicine)</td>
</tr>
<tr>
<td></td>
<td>Internal Medicine</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>Gastroenterology</td>
</tr>
<tr>
<td>Surgery</td>
<td>General Surgery</td>
</tr>
<tr>
<td></td>
<td>Facial Plastic Surgery</td>
</tr>
<tr>
<td></td>
<td>Vascular Surgery</td>
</tr>
<tr>
<td>Obstetrics and Gynecology</td>
<td>Gynecology</td>
</tr>
<tr>
<td></td>
<td>Obstetrics and Gynecology</td>
</tr>
<tr>
<td>Hematology/Oncology</td>
<td>Hematology/Oncology</td>
</tr>
<tr>
<td></td>
<td>Radiation Oncology</td>
</tr>
<tr>
<td>Nephrology</td>
<td>Nephrology</td>
</tr>
<tr>
<td>Ophthalmology</td>
<td>Ophthalmology</td>
</tr>
<tr>
<td>Orthopedics/Neurological Surgery</td>
<td>Neurological Surgery</td>
</tr>
<tr>
<td></td>
<td>Orthopedics</td>
</tr>
<tr>
<td></td>
<td>Orthopedic Surgery of the Spine</td>
</tr>
<tr>
<td>Otolaryngology</td>
<td>Otolaryngology</td>
</tr>
<tr>
<td>Neurology</td>
<td>Neurology</td>
</tr>
<tr>
<td>Pathology</td>
<td>Pathology</td>
</tr>
<tr>
<td>Pediatrics</td>
<td>Pediatrics</td>
</tr>
<tr>
<td>Podiatry</td>
<td>Podiatry</td>
</tr>
<tr>
<td>Psychiatry</td>
<td>Psychiatry</td>
</tr>
<tr>
<td>Pulmonary Diseases</td>
<td>Pulmonary Diseases</td>
</tr>
<tr>
<td>Radiology</td>
<td>Radiology</td>
</tr>
</tbody>
</table>
### 4.4 Opioid/Buprenorphine Considerations

Buprenorphine is an opioid partial agonist commonly used to provide medication assisted treatment (MAT) of opioid use disorder. In order to help differentiate between opioids for pain treatment versus MAT, all buprenorphine products have been excluded from the opioid metrics, except for the overlapping opioid, and overlapping opioid and benzodiazepine metrics on page one of the report card. The description for each opioid metric in the prescriber report card identifies whether buprenorphine products were included or excluded from the calculation. Buprenorphine products are also excluded from the morphine milligram equivalent dose calculations as described in Section 4.5 Morphine Milligram Equivalent Dose Information.

### 4.5 Morphine Milligram Equivalent Dose Information

Morphine milligram equivalent dose calculations are based on a morphine equivalent dose conversion table that is provided by the U.S. Centers for Disease Control and Prevention. The table does not include conversion factors for buprenorphine products based on the following guidance from CDC.

“Buprenorphine products are listed in this file but do not have an associated MME conversion factor. The conversion factors for drugs prescribed or provided as part of medication-assisted treatment for opioid use disorder should not be used to benchmark against dosage thresholds meant for opioids prescribed for pain. These buprenorphine products, as partial opioid agonists, are not expected to be associated with overdose risk in the same dose-dependent manner as doses for full agonist opioids.”

### 4.6 Prescriber Report Card Calculations

This section documents how each specific KASPER Prescriber Report Card metric is calculated for the specified prescriber report card period. All calculations exclude controlled substance compounds. The total number of patients for whom you prescribed one or more Schedule II through V controlled substances is listed in the report header at the top of each page.

#### 4.6.1 Patients receiving three or more days of overlapping opioid
prescriptions from all prescribers
This metric lists the number and percentage of your patients for whom you prescribed one or more Schedule II through V controlled substances, who received three or more days of overlapping opioid prescriptions from any prescribers based on the prescription date filled.

Percentage calculation:
*Numerator:* the number of patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions, who had an overlap of three days or more for opioid prescriptions that were prescribed by you or any other prescriber.
*Denominator:* the total number of patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions.

4.6.2 Patients receiving overlapping opioid and benzodiazepine/sedative prescriptions from all prescribers
This metric lists the number and percentage of your patients for whom you prescribed one or more Schedule II through V controlled substances, who received overlapping opioid and benzodiazepine or sedative prescriptions from any prescribers based on the prescription date filled.

Percentage calculation:
*Numerator:* the number of patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions, who had an overlap of any number of days for opioid prescription(s) with benzodiazepine or sedative prescription(s), that were prescribed by you or any other prescriber.
*Denominator:* the total number of patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions.

4.6.3 Patients for whom you prescribed benzodiazepines or sedatives
This metric lists the number and percentage of your patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions for benzodiazepines or sedatives, based on the prescription date prescribed.

Percentage calculation:
*Numerator:* the number of patients for whom you prescribed one or more Schedule II through V controlled substance benzodiazepine or sedative prescriptions.
*Denominator:* the total number of patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions.

4.6.4 Patients for whom you prescribed stimulants
This metric lists the number and percentage of your patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions for stimulants, based on the prescription date prescribed.

Percentage calculation:
*Numerator:* the number of patients for whom you prescribed one or more Schedule II through V controlled substance stimulant prescriptions.
Denominator: the total number of patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions.

4.6.5 Patients for whom you prescribed opioids excluding buprenorphine products
This metric lists the number and percentage of your patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions for opioids, excluding buprenorphine products, based on the prescription date prescribed.

Percentage calculation:
Numerator: the number of patients for whom you prescribed one or more Schedule II through V controlled substance opioid prescriptions excluding all buprenorphine products.
Denominator: the total number of patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions.

4.6.6 Average daily morphine milligram dosage for your patients receiving opioids excluding buprenorphine products
This metric lists the average daily morphine milligram equivalent dose level for your patients who are receiving Schedule II through V opioid prescriptions from any prescriber, excluding buprenorphine products, based on the prescription date prescribed.

4.6.7 Patients for whom you prescribed buprenorphine medication assisted treatment products
This metric lists the number and percentage of your patients for whom you prescribed one or more controlled substance prescriptions for buprenorphine medication assisted treatment products, based on the prescription date prescribed.

Percentage calculation:
Numerator: the number of patients for whom you prescribed one or more buprenorphine medication assisted treatment products.
Denominator: the total number of patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions.

4.6.8 Average daily milligram dosage for your patients receiving buprenorphine medication assisted treatment products
This metric lists the average daily milligram dose level for your patients to whom you are prescribing buprenorphine products for medication assisted treatment, based on the prescription date prescribed.

4.6.9 Patients receiving controlled substance prescriptions from five or more different prescribers
This metric lists the number and percentage of your patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions, who are receiving controlled
substance prescriptions from five or more different prescribers including yourself, based on the prescription date filled.

Percentage calculation:
_Numerator:_ the number of your patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions, who received controlled substance prescriptions from a total of five or more different prescribers including yourself.
_Denominator:_ the total number of patients for whom you prescribed one or more Schedule II through V controlled substance prescriptions.

### 4.6.10 Prescribing comparison for opioids excluding buprenorphine products

_All buprenorphine products are excluded from the calculations for this metric._

This metric lists the total number of Schedule II through V opioid prescriptions and doses that you wrote based on the prescription date written. Your prescription and dose figures are compared with the following.

- The average number of opioid prescriptions and doses written by all prescribers with a Kentucky DEA address. These averages are calculated by dividing the total number of opioid prescriptions and doses written by Kentucky prescribers, by the total number of Kentucky prescribers who wrote at least one opioid prescription.
- The average number of opioid prescriptions and doses written by all prescribers with a Kentucky DEA address who list the same area of work that you do in their KASPER account. These averages are calculated by dividing the total number of opioid prescriptions and doses written by Kentucky prescribers listing the same area of work as you do in their KASPER account, by the total number of Kentucky prescribers listing the same area of work in their KASPER account and who wrote at least one opioid prescription.

### 4.6.11 Prescribing comparison for benzodiazepines

This metric lists the total number of Schedule II through V benzodiazepine prescriptions and doses that you wrote based on the prescription date written. Your prescription and dose figures are compared with the following.

- The average number of benzodiazepine prescriptions and doses written by all prescribers with a Kentucky DEA address. These averages are calculated by dividing the total number of benzodiazepine prescriptions and doses written by Kentucky prescribers, by the total number of Kentucky prescribers who wrote at least one benzodiazepine prescription.
- The average number of benzodiazepine prescriptions and doses written by all prescribers with a Kentucky DEA address who list the same area of work that you do in their KASPER account. These averages are calculated by dividing the total number of benzodiazepine prescriptions and doses written by Kentucky prescribers listing the same area of work as you do in their KASPER account, by the total number of Kentucky prescribers listing the same area of work in their KASPER account and who wrote at least one benzodiazepine prescription.
4.6.12 Prescribing comparison for sedatives

This metric lists the total number of Schedule II through V sedative prescriptions and doses that you wrote based on the prescription date written. Your prescription and dose figures are compared with the following.

- The average number of sedative prescriptions and doses written by all prescribers with a Kentucky DEA address. These averages are calculated by dividing the total number of sedative prescriptions and doses written by Kentucky prescribers, by the total number of Kentucky prescribers who wrote at least one sedative prescription.
- The average number of sedative prescriptions and doses written by all prescribers with a Kentucky DEA address who list the same area of work that you do in their KASPER account. These averages are calculated by dividing the total number of sedative prescriptions and doses written by Kentucky prescribers listing the same area of work as you do in their KASPER account, by the total number of Kentucky prescribers listing the same area of work in their KASPER account and who wrote at least one sedative prescription.

4.6.13 Prescribing comparison for stimulants

This metric lists the total number of Schedule II through V stimulant prescriptions and doses that you wrote based on the prescription date written. Your prescription and dose figures are compared with the following.

- The average number of stimulant prescriptions and doses written by all prescribers with a Kentucky DEA address. These averages are calculated by dividing the total number of stimulant prescriptions and doses written by Kentucky prescribers, by the total number of Kentucky prescribers who wrote at least one stimulant prescription.
- The average number of stimulant prescriptions and doses written by all prescribers with a Kentucky DEA address who list the same area of work that you do in their KASPER account. These averages are calculated by dividing the total number of stimulant prescriptions and doses written by Kentucky prescribers listing the same area of work as you do in their KASPER account, by the total number of Kentucky prescribers listing the same area of work in their KASPER account and who wrote at least one stimulant prescription.

4.6.14 Average daily morphine milligram equivalent for patients receiving opioids excluding buprenorphine

All buprenorphine products are excluded from the calculations for this metric.

This metric lists the total number of Schedule II through V opioid doses that you wrote based on the prescription date written. Your opioid dose figures are compared with the following.

- The average number of opioid doses written by all prescribers with a Kentucky DEA address. This average is calculated by dividing the total number of opioid doses written by Kentucky prescribers, by the total number of Kentucky prescribers who wrote at least one opioid prescription.
- The average number of opioid doses written by all prescribers with a Kentucky DEA address who list the same area of work that you do in their KASPER account. This average is calculated by dividing the total number of opioid doses written by Kentucky prescribers listing the same area of work as you do in their KASPER account, by the
total number of Kentucky prescribers listing the same area of work in their KASPER account and who wrote at least one opioid prescription. This metric also lists the average daily morphine equivalent dose (MED) level for patients for whom you prescribed one or more opioids. Your average daily MED is compared with the following.

- The average daily MED level for opioid prescriptions written by all prescribers with a Kentucky DEA address. This average is calculated by dividing the total patient daily morphine equivalent doses for opioid prescriptions written by Kentucky prescribers, by the total number of Kentucky prescribers who wrote at least one opioid prescription.
- The average daily MED level for opioid prescriptions written by all prescribers with a Kentucky DEA address who list the same area of work that you do in their KASPER account. This average is calculated by dividing the total patient daily morphine equivalent doses for opioid prescriptions written by Kentucky prescribers listing the same area of work as you do in their KASPER account, by the total number of Kentucky prescribers listing the same area of work in their KASPER account and who wrote at least one opioid prescription.

### 4.7 Medication Assisted Treatment Metrics

Not all Kentucky prescribers provide medication assisted treatment with buprenorphine products; however, eKASPER stakeholders requested that data about MAT be included in the prescriber report cards. Page one of the report card includes metrics on the total number and percent of patient’s receiving treatment with buprenorphine products specifically for MAT, along with the average daily milligram dose for those patients receiving treatment with buprenorphine MAT products.

Please note: this data reflects the average daily buprenorphine milligram dose level, not the morphine equivalent dose level as explained in Section 4.5 Morphine Milligram Equivalent Dose Information.
5 Prescriber Report Card Example

- **Number of your patients who received three days or more of overlapping opioid prescriptions from all prescribers:** 219 (34%)
- **Number of your patients who received overlapping opioid and benzodiazepine/sedative prescriptions from all prescribers:** 142 (22%)
- **Number of your patients for whom you prescribed benzodiazepines/sedatives:** 153 (23.8%)
- **Number of your patients for whom you prescribed stimulants:** 390 (60.7%)
- **Number of your patients for whom you prescribed opioids (excluding buprenorphine products):** 124 (19.3%)
- **Average daily morphine milligram equivalent dosage level of your patients receiving opioid prescriptions (excluding buprenorphine products):** 96
- **Number of your patients who prescribed buprenorphine medication assisted treatment products:** 321 (50.0%)
- **Average daily milligram dose for patients for whom you prescribed buprenorphine medication assisted treatment products:** 16
- **Number of your patients receiving controlled substance prescriptions from five or more different prescribers:** 12 (1.9%)
Opioids Excluding Buprenorphine Products

Prescriptions Written

Doses Prescribed

<table>
<thead>
<tr>
<th></th>
<th>State Avg.</th>
<th>Specialty Avg.</th>
<th>You</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescription Count</td>
<td>400</td>
<td>350</td>
<td>250</td>
</tr>
<tr>
<td>Dosage Count</td>
<td>29400</td>
<td>23512</td>
<td>18000</td>
</tr>
</tbody>
</table>

Benzodiazepines

Prescriptions Written

Doses Prescribed

<table>
<thead>
<tr>
<th></th>
<th>State Avg.</th>
<th>Specialty Avg.</th>
<th>You</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescription Count</td>
<td>180</td>
<td>200</td>
<td>571</td>
</tr>
<tr>
<td>Dosage Count</td>
<td>15000</td>
<td>18000</td>
<td>35550</td>
</tr>
</tbody>
</table>

Sedatives

Prescriptions Written

Doses Prescribed

<table>
<thead>
<tr>
<th></th>
<th>State Avg.</th>
<th>Specialty Avg.</th>
<th>You</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescription Count</td>
<td>17</td>
<td>9</td>
<td>63</td>
</tr>
<tr>
<td>Dosage Count</td>
<td>1200</td>
<td>642</td>
<td>1800</td>
</tr>
</tbody>
</table>

Stimulants

Prescriptions Written

Doses Prescribed

<table>
<thead>
<tr>
<th></th>
<th>State Avg.</th>
<th>Specialty Avg.</th>
<th>You</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescription Count</td>
<td>321</td>
<td>205</td>
<td>115</td>
</tr>
<tr>
<td>Dosage Count</td>
<td>1278</td>
<td>457</td>
<td>231</td>
</tr>
</tbody>
</table>

Patients Receiving Opioids - Average Daily Morphine Equivalent Dosage Level (excluding buprenorphine)

Doses Prescribed

Average Patient Daily Opioid MED Level

<table>
<thead>
<tr>
<th></th>
<th>State Avg.</th>
<th>Specialty Avg.</th>
<th>You</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>60</td>
<td>90</td>
<td></td>
</tr>
</tbody>
</table>